Diagnostic mutationnel rapide Idylla™ : applications théranostiques actuelles et futures

Bourhis, Amélie; Remoué, Annabelle; Samaison, Laura; Uguen, Arnaud

doi:10.1016/j.annpat.2021.12.007

Cited by 2 publications

(3 citation statements)

References 104 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Considering the Idylla platform, a French meta-analysis calculated a sensibility of 99.3% and specificity of 96.8% with a positive predictive value of 97.4% and negative predictive value of 99.1% for KRAS. Similarly, they reported a sensibility of 96.7% and 98.8%, a specificity of 99.7% and 99.3%, a PPV of 99% and 98%, with a NPP of 98.9% and 99.6% for NRAS and BRAF respectively [27].…”

Section: Discussionmentioning

confidence: 87%

Molecular characteristics of left-sided, advanced stage colorectal cancer: A Mexican perspective

Maria José,

Braulio,

Jean

et al. 2024

J Gastroenterol Res Pract

View full text Add to dashboard Cite

Background: Predictive molecular markers based on the consensus molecular classification of colorectal carcinoma are tested following expert recommendations. Specifically, they are tested when target molecular therapy is being considered for treatment. Their presence depends on biology but their frequency seems to be increased in advanced stages. Objective: We developed a study of cases of left-sided CRC in advanced clinical stages from a cohort of Mexican patients to evaluate the presence of predictive molecular markers. Method: Predictive molecular markers were analyzed, including BRAF, KRAS, NRAS and mismatch repair genes, in cases of advanced, left-sided colorectal carcinoma.

show abstract

Section: Discussionmentioning

confidence: 87%

Molecular characteristics of left-sided, advanced stage colorectal cancer: A Mexican perspective

Maria José,

Braulio,

Jean

et al. 2024

J Gastroenterol Res Pract

View full text Add to dashboard Cite

show abstract

“…Selected tumour areas were macrodissected and then transferred in the IGFA cartridge (one 5 µm thick section of one tissue area only per cartridge), itself inserted in the instrument as previoulsy published for other Idylla tests 13 14 19. Inside the cartridge, the sample was homogenised and cells were lysed using a combination of high-intensity-focused ultrasounds, enzymatic/chemical digestion and heat.…”

Section: Methodsmentioning

confidence: 99%

“…Beyond NGS and morphological methods, the Idylla system (Biocartis, Mechelen, Belgium) has been developed as a standalone molecular platform that can be easily implemented in pathology laboratories to detect quickly and simply oncogenic mutations 13 14. This methodology consists in a cartridge-based and fully automated medical device able to perform molecular analyses in less than 1 day, even in a laboratory without any experience in molecular analyses.…”

Section: Introductionmentioning

confidence: 99%

Performances of the Idylla GeneFusion Assay: contribution to a rapid diagnosis of targetable gene fusions in tumour samples

et al. 2023

Self Cite

View full text Add to dashboard Cite

AimsWe aimed to evaluate the performances of the Idylla GeneFusion Assay (IGFA) designed to detect, in a single, rapid and fully automated assay,ALK,ROS1,RET,NTRK1,NTRK2andNTRK3gene fusions andMETexon 14 skipping in cancer samples.MethodsBased on a set of tumours enriched in cases with gene fusions, we applied the IGFA to tumour areas of various sizes and tumour cell contents. IGFA results were compared with those obtained with other methods (immunohistochemistry, fluorescent in situ hybridisation, DNA and RNA next-generation sequencing).ResultsWe selected 68 tumours: 49 cases with known gene fusions (8ALK, 8ROS1, 5RET, 7NTRK1, 3NTRK2and 6NTRK3ones) orMETexon 14 skipping mutations (12 cases) and 19 cases with no fusion and noMETmutation. We performed 128 IGFA tests on distinct tissue areas. The global sensitivity and specificity of the IGFA were, respectively, 62.82% and 99.2% with variations between molecular targets and tissue areas. Of note, 72.5% sensitivity and 98.79% specificity were obtained in 37 tissue areas fulfilling the manufacturer’s recommendations (ie, at least 10% of tumour cells in at least 20 mm² of tissue area). The rate of non-conclusive results was higher in small samples with low percentages of tumour cells.ConclusionsThe IGFA could contribute to the rapid detection of targetable gene fusions and mutations, especially in context of rapidly growing cancers requiring urgent therapeutic choices.

show abstract

Diagnostic mutationnel rapide Idylla™ : applications théranostiques actuelles et futures

Cited by 2 publications

References 104 publications

Molecular characteristics of left-sided, advanced stage colorectal cancer: A Mexican perspective

Molecular characteristics of left-sided, advanced stage colorectal cancer: A Mexican perspective

Performances of the Idylla GeneFusion Assay: contribution to a rapid diagnosis of targetable gene fusions in tumour samples

Contact Info

Product

Resources

About